

D₃
cont
complementarity determining region to partially or fully replace said complementarity determining region.

D₄
24. The composition of Claim 67 wherein said protein fragment or peptide comprising a T cell receptor antagonist derived from proteolipid protein comprises a peptide analog of [a peptide agonist wherein said peptide agonist is capable of activating a T cell response to] proteolipid protein.

D₅
29. The composition of claim 27 wherein said composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist derived from proteolipid protein is covalently joined to said immunoglobulin or portion thereof.

D₆
66. A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a [known] T cell receptor antagonist derived from proteolipid protein, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules.

D₇
68. The composition of Claim 66, wherein said protein fragment or peptide comprising [**the T cell receptor antagonist**] a T cell receptor antagonist derived from proteolipid protein is covalently linked to said immunoglobulin or portion thereof.

D₈
69. The composition of Claim 68, wherein said protein fragment or peptide comprising a T cell receptor antagonist derived from proteolipid protein comprises a peptide analog of [a peptide agonist wherein said peptide agonist is capable of activating a T cell response to] proteolipid protein.

D₉
72. The composition of Claim 67, wherein the composition comprises a fusion protein in which said protein fragment or peptide comprising [**said T cell receptor antagonist**] comprising a T cell receptor antagonist derived from proteolipid protein is covalently joined to said immunoglobulin or portion thereof.

D₁₀
73. The composition of Claim 72, wherein said protein fragment or peptide comprising [**said T cell receptor antagonist**] a T cell receptor antagonist derived from proteolipid protein is positioned within at least one complementary determining region to partially or fully replace said complementarity determining region.